FDA clears InspireMD's CGuard Prime for TCAR on 50-patient trial
The FDA approved InspireMD's CGuard Prime stent system for transcarotid artery revascularization, an 80-centimeter version used with embolic protection. It rests on a 50-patient, single-arm trial with no comparison group, and the results are company-reported rather than peer-reviewed.
- Original source: medicaldaily.com.
- The source published it on Nov 15, 2026 at 2:36 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA has approved InspireMD's CGuard Prime stent system for transcarotid artery revascularization, the company said Nov. 12. The green light comes as a supplement to the device's existing approval and covers an 80-centimeter version of the system, used alongside an embolic protection system. TCAR is a less invasive way to open narrowed neck arteries and cut stroke risk.
The decision leans on CGUARDIANS II, a single-arm study of 50 patients across 11 U.S. sites. At 30 days, InspireMD reported 100% acute device success and zero deaths, strokes, heart attacks or stent clots. But there's no comparison group, so the trial can't show CGuard Prime beats other TCAR stents. Fifty patients is also too small to catch rare complications, and 30 days is too short to judge long-term stroke prevention. The results so far are the company's own and haven't been peer-reviewed.
CGuard Prime wears a fine mesh coating InspireMD calls MicroNet, built to pin plaque against the artery wall. The FDA cleared it in June 2025 for catheter-based stenting based on a 316-patient trial. Its history isn't spotless: in May 2026, InspireMD recalled a longer 135-centimeter delivery system after it missed performance expectations, per MassDevice. That recall didn't touch the 80-centimeter TCAR version.
InspireMD also points to its earlier 316-patient C-GUARDIANS trial, which logged major adverse event rates of 0.95% at 30 days and 1.93% at a year -- numbers the company calls the lowest of any pivotal carotid stenting study. Carotid stenting is gaining ground generally. In the NIH-funded CREST-2 trials, adding stenting to intensive medical therapy dropped four-year stroke risk from about 6% to just under 3% in people with severe narrowing and no recent stroke, according to University of Utah Health. Those results cover stenting broadly, not CGuard Prime or TCAR specifically.
TCAR works through a small incision at the neckline above the collarbone, with blood flow temporarily reversed so debris gets pulled away from the brain while the stent goes in, the Society for Vascular Surgery explains. Risks include stroke, heart attack, artery or cranial nerve damage and bleeding at the incision. InspireMD estimates more than 35,000 TCAR procedures happen in the U.S. every year.
Candidates are usually people with significant carotid narrowing -- with or without stroke symptoms -- who face higher risk from open surgery, including older adults and those with heart disease, prior neck surgery or radiation, or tricky anatomy. Many patients do fine on medicines alone. Most TCAR patients spend one night in the hospital, and follow-up imaging plus clot-preventing drugs are still required. Patients can ask their surgeon how many TCARs they perform, which stent they use and why, and whether insurance covers it before booking.
TopicsInspireMD · CGuard Prime · FDA · TCAR · CGUARDIANS II · CREST-2 · Society for Vascular Surgery · MicroNet
Source: medicaldaily.com
Written by AI from verified reporting. Not financial advice.

